Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06575374
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Cell Therapy

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Letermovir — DRUG
    Given by mouth or intravenously

Study Details

The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.

Key Dates

Start date
Dec 12, 2024
Status verified
Jan 2026
Primary completion
Aug 1, 2026
Completion
Aug 1, 2027

Study Design

Enrollment
36 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION

Arms

  • Experimental: Open label Single arm: Letermovir
    Participants will be identified/recruited/screened from the Lymphoma and Stem Cell Transplantation and Cellular Therapy services at MD Anderson Cancer Center.

Primary Outcome Measure

Safety and Adverse Events (AEs) [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
George Chen, MD
[email protected]
713-792-3630
George Chen, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies